Business - Monitor   

Ranbaxy gets USFDA nod

MUMBAI: Ranbaxy Laboratories (RLL) has announced that Ranbaxy Pharmaceuticals Inc (RPI), a wholly owned subsidiary of RLL has received tentative approval from the U.S. Food and Drug Administration to market benazepril hydrochloride tablets in 5mg, 10mg, 20mg and 40mg strengths. In 2002, sales of this dosage totalled $332.50 million, according to a BSE release.

Printer friendly page  
Send this article to Friends by E-Mail

Business

News: Front Page | National | Southern States | Other States | International | Opinion | Business | Sport | Miscellaneous |
Advts: Classifieds | Employment | Obituary |

Stories in this Section

• UTI Bank's offer to institutions
• Safety issues in asbestos industry
• GM launches Chevrolet SUV
• Nasscom, Hewitt to study IT cos. pay structure
• IDBI cuts rate for Flexibonds-18 series
• Initial bids for Manganese Ore divestment soon
• Jindal rail mill goes on hot trial
• UPS to launch Internet shipping
• Early gains not held on BSE
• Stock Market Index
• Exchange rates
• Bullion rates
• Ranbaxy gets USFDA nod
• IDBI Bank to raise TIER II capital
• BoB launches new SB account
• TMB raises deposit rates
• GE Shipping enters new contract
• Two new RBI Executive Directors

Copyright © 2003, The Hindu. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu